{
  "docId": "019de076-341d-707d-8f10-e094a3d9771c",
  "docSlug": "c0c2a81b97260bf20014943df2470872",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 39,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "why_now",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a specific callout for a Blackbox warning on existing competitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-341d-707d-8f10-e094a3d9771c/25",
  "deckHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c",
  "deckJsonHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json",
  "deckAnchorHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "callout",
      "text": "EQ101 is positioned as a well-tolerated and effective alternative to JAK inhibitors",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2c6fda2-a091-4f9d-9257-cb96c51637ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.23,
        "x": 0.51,
        "y": 0.35
      },
      "kind": "chart",
      "text": "I am concerned about the safety of oral JAK inhibitors for my AA patients",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abf07ab1-db9a-4c94-a287-be59ab9bfb64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.05,
        "y": 0.33
      },
      "kind": "list",
      "text": "Currently approved and late-stage pipeline drugs are all JAK inhibitors. There remains a chronic need, without a safe chronic treatment. Dermatologists indicate safety concerns are the primary barriers to JAKi use in AA patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a0c3047-469a-42f0-a69d-c9dd3903bbca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.42,
        "x": 0.05,
        "y": 0.73
      },
      "kind": "metric",
      "text": "79% of physicians surveyed, believe there is an extremely high unmet medical need*",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4384ab31-6f5c-45db-8cc7-eebffafdfcab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.12,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "* Spherix Global Insights; ** Olumiant Package Insert",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3f438d4-8323-4a2e-8e31-b1b27ca4edef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.22,
        "x": 0.76,
        "y": 0.33
      },
      "kind": "table",
      "text": "Blackbox warning: WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f700de68-8d69-472d-b439-c6b6b57d7af1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Large Unmet Need in Alopecia Areata",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7203cc49-d2a7-4daf-b40e-3f8994b730da",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 25,
      "from": 25,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "04b5f862-a1da-427a-9706-844a7a78d8b4",
      "evidence": "The cost of inaction is implied in the discussion of unmet need.",
      "position": 1,
      "objective": "Unmet need in Alopecia Areata",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}